04:45 AM EDT, 03/25/2025 (MT Newswires) -- Entero Therapeutics ( ENTO ) said Monday it has entered into a rescission agreement to cancel and unwind its business combination with ImmunogenX that closed last year.

The agreement is subject to closing conditions, including Entero shareholder approval on or before June 30.

"Unwinding this transaction puts Entero back in the game and ultimately strengthens our balance sheet, refocuses our value creation strategy, and positions us for long-term success," said Richard Paolone, chief executive of Entero.

Entero also said it has named Anna Skowron as chief financial officer, effective March 3.